Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Ikke-invasiv median nervestimulering for å dempe atrietakyarytmier etter kateterablasjon for atrieflimmer (NEUROPULSE)

6. november 2026 oppdatert av: Vivek Reddy, Icahn School of Medicine at Mount Sinai

Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.

The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:

  1. early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
  2. AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).

The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.

Studieoversikt

Status

Fullført

Forhold

Detaljert beskrivelse

Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).

Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).

In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.

Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.

Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.

Studietype

Intervensjonell

Registrering (Faktiske)

51

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine at Mount Sinai

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  • Men and women ages ≥18 years
  • Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
  • Ability and willingness to sign an informed consent form.
  • Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.

Exclusion Criteria

  • Rheumatic heart disease
  • Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
  • Moderate to severe mitral stenosis or history of mitral valve replacement
  • Pacemaker or CRTD or any implanted electrical stimulating device
  • Unilateral or bilateral vagotomy
  • Peripheral neuropathy affecting the tested upper extremity.
  • Severe heart failure (New York Heart Association Class III or IV) within 90 days.
  • Recent (within 90 days) stroke or transient ischemic attack.
  • Recent (within 90 days) myocardial infarction.
  • Pregnancy or breast feeding.
  • Life expectancy <1 year for any medical condition
  • Currently enrolled in another study that would interfere with this study
  • Unsuitable for participating in the study according to attending physician

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Participants with CardiaCare RR2

Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users.

CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF.

Sham-komparator: Participants with Sham Device

Sham device will be dispensed, which will create a sensation but not provide therapy

Sham device will be dispensed, which will create a sensation but not provide therapy

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
AF/AFL occurrence
Tidsramme: at 2-months and 6-months post-ablation procedure

Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG.

at 2-months and 6-months post-ablation procedure

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall akuttbesøk
Tidsramme: 6 måneder etter ablasjon
6 måneder etter ablasjon
Antall sykehusinnleggelser
Tidsramme: 6 måneder etter ablasjon
6 måneder etter ablasjon
Antall kardioversjoner
Tidsramme: 6 måneder etter ablasjon
6 måneder etter ablasjon
Antall ablasjonsgjentakelser
Tidsramme: 6 måneder etter ablasjon
6 måneder etter ablasjon
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsramme: 2-month and 6-month post-ablation procedure

Time to first AT or AF recurrence measured by CardiaCare RR2

2-month and 6-month post-ablation procedure
Number of arrythmia occurrences
Tidsramme: 2-month and 6-month post-ablation procedure

Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG.

2-month and 6-month post-ablation procedure
Number of Atrial Arrythmia Symptoms
Tidsramme: 6-month post-ablation procedure

Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation.

6-month post-ablation procedure
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Tidsramme: 6 months post-ablation

Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation.

6 months post-ablation
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
Tidsramme: Baseline, 2-months, and 6-months

The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms.

Baseline, 2-months, and 6-months
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
Tidsramme: Baseline, 2-months, and 6-months

The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens.

Baseline, 2-months, and 6-months
Change in PAC/AT/AFL before and after treatment with RR2
Tidsramme: Baseline and 6-month post-ablation

Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device.

Baseline and 6-month post-ablation
Change in Heart Rate Variability (HRV)
Tidsramme: Baseline and 6-month post-ablation

Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience.

Baseline and 6-month post-ablation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
  • Hovedetterforsker: Mohit Turagam, MD, Icahn School of Medicine at MS

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. oktober 2024

Primær fullføring (Faktiske)

30. juli 2026

Studiet fullført (Faktiske)

30. juli 2026

Datoer for studieregistrering

Først innsendt

19. desember 2024

Først innsendt som oppfylte QC-kriteriene

19. desember 2024

Først lagt ut (Faktiske)

27. desember 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere